Targeting LDL: Is lower better and is it safe?

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 28, Issue 3, 2014, Pages 309-324

  Stein, Evan A ^a   Raal, Frederick J ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Friedewald formula; LDL cholesterol; PCSK9 inhibitors; statins

Indexed keywords

ALIROCUMAB; APOLIPOPROTEIN B; ATORVASTATIN; BILE ACID SEQUESTRANT; CHOLESTEROL; EVOLOCUMAB; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; KEXIN; LAROPIPRANT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; HYPOCHOLESTEROLEMIC AGENT;

ACUTE CORONARY SYNDROME; ARTICLE; BILE ACID SYNTHESIS; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL PRACTICE; DIABETES MELLITUS; FOLLOW UP; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPOBETALIPOPROTEINEMIA; LOSS OF FUNCTION MUTATION; PRIMARY PREVENTION; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SECONDARY PREVENTION; TREATMENT DURATION; UPREGULATION; ANTAGONISTS AND INHIBITORS; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL (TOPIC); MOLECULARLY TARGETED THERAPY; RISK FACTOR;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; HUMANS; MOLECULAR TARGETED THERAPY; RISK FACTORS;

EID: 84901250910     PISSN: 1521690X     EISSN: 15321908     Source Type: Journal    
DOI: 10.1016/j.beem.2013.10.010     Document Type: Review

References (66)

1. The lipid research clinics coronary primary prevention trial results I. Reduction in incidence of coronary heart disease JAMA 251 1984 351 364
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
3. P.M. Ridker, E. Danielson, and F.A. Fonseca et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
4. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults: the expert panel Arch Intern Med 148 1988 36 69
5. Expert panel on detection evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment Panel III) JAMA 285 2001 2486 2497
6. European Association for Cardiovascular Prevention & Rehabilitation, Z. Reiner, A.L. Catapano, G. De Backer ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Eur Heart J 32 2011 1769 1818
7. J. Shepherd, S.M. Cobbe, and I. Ford et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group N Engl J Med 333 1995 1301 1307
8. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 339 1998 1349 1357
9. J.C. LaRosa, S.M. Grundy, and D.D. Waters et al. Treating to new targets: I. Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
10. R.R. Giraldez, R.P. Giugliano, and S. Mohanavelu et al. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22) analysis J Am Coll Cardiol 52 2008 914 920
11. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
12. J. Armitage, L. Bowman, and K. Wallendszus et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial Lancet 376 2010 1658 1669
13. F.M. Sacks, M.A. Pfeffer, and L.A. Moye et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators N Engl J Med 335 1996 1001 1009
14. J. Hsia, J.G. MacFadyen, and J. Monyak et al. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) J Am Coll Cardiol 57 2011 1666 1675
15. Cholesterol Treatment Trialists' (CTT) Collaborators The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials Lancet 380 2012 581 590
16. T.R. Pedersen, O. Faergeman, J.J. Kastelein Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial JAMA 294 2005 2437 2445
17. C.P. Cannon, R.P. Giugliano, M.A. Blazing IMPROVE-IT Investigators Rationale and design of IMPROVE-IT (IMProved reduction of outcomes: vytorin efficacy international trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes Am Heart J 156 2008 826 832
18. IMPROVE-IT: Examining outcomes in subjects with acute coronary syndrome: vytorin (ezetimibe/simvastatin) vs simvastatin (P04103 AM5). http://clinicaltrials.gov/ct2/show/NCT00202878 [accessed 04.10.13].
19. HPS2-THRIVE Collaborative Group HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment Eur Heart J 34 2013 1279 1291
20. Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
21. E.A. Stein, and G.D. Swergold Potential of proprotein convertase Subtilisin/Kexin type 9 based therapeutics Curr Atheroscler Rep 15 2013 310 10.1007/s11883-013-0310-3
22. E.A. Stein, S. Mellis, and G.D. Yancopoulos et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol N Engl J Med 366 2012 1108 1118
23. J.M. McKenney, M.J. Koren, and D.J. Kereiakes et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy J Am Coll Cardiol 59 2012 2344 2353
24. E.A. Stein, D. Gipe, and J. Bergeron et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial Lancet 380 2012 29 36
25. E.M. Roth, J.M. McKenney, and C. Hanotin et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia N Engl J Med 367 2012 1891 1900
26. F. Raal, R. Scott, and R. Somaratne et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial Circulation 126 2012 2408 2417
27. D. Sullivan, A.G. Olsson, and R. Scott et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial JAMA 308 2012 2497 2506
28. Evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with alirocumab SAR236553 (REGN727) (ODYSSEY outcomes). http://clinicaltrials.gov/ct2/show/NCT01663402?term=alirocumab&rank=11 [accessed 15.08.13].
29. Further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER). http://clinicaltrials.gov/ct2/show/ NCT01764633?term=AMG+145&rank=18 [accessed 15.08.13].
30. The AIM-HIGH Investigators W.E. Boden, J.L. Probstfield, and T. Anderson et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
31. The ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
32. P.J. Barter, M. Caulfield, M. Eriksson ILLUMINATE Investigators Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
33. G.G. Schwartz, A.G. Olsson, M. Abt dal-OUTCOMES Investigators Effects of Dalcetrapib in patients with a recent acute coronary syndrome N Engl J Med 367 22 2012 Nov 29 2089 2099
34. M.R. Law, N.J. Wald, and S.G. Thompson By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 308 1994 367 372
35. M.R. Law, N.J. Wald, and A.R. Rudnicka Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis BMJ 326 2003 1423 1429
36. P.A. Davis, and T.M. Forte Neonatal umbilical cord blood lipoproteins: isolation and characterization of intermediate density and low density lipoproteins Arteriosclerosis 2 1982 37 43
37. J.H. O'Keefe, L. Cordian, and W.H. Harris et al. Optimal low-density lipoprotein is 50-70 mg/dL J Am Coll Cardiol 43 2004 2142 2146
38. Z. Chen, R. Peto, and R. Collins et al. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations BMJ 303 1991 276 282
39. J.C. Cohen, E. Boerwinkle, and T.H. Mosley Jr. et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N Engl J Med 354 2006 1264 1272
40. M. Benn, B.G. Nordestgaard, and P. Grande et al. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses J Am Coll Cardiol 55 2010 2833 2842
41. B.A. Ference, W. Yoo, and I. Alesh et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease a Mendelian randomization analysis J Am Coll Cardiol 60 2012 2631 2639
42. M.S. Brown, and J.L. Goldstein Lowering LDL - not only how low, but how long? Science 311 2006 1721 1723
43. W.T. Friedewald, R.I. Levy, and D.S. Fredrickson Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 1972 499 502
44. H. Scharnagl, M. Nauck, and H. Wieland et al. The Friedewald formula underestimates LDL cholesterol at low concentrations Clin Chem Lab Med 39 2001 426 431
45. S.S. Martin, M.J. Blaha, and M.B. Elshazly et al. Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications J Am Coll Cardiol 20 2013 732 739
46. Turner T, Plunkett N, Miller J, et al. Validity of calculated LDL cholesterol by the Friedewald formula compared to LDL cholesterol measured by ultracentrifugation in patients with very low LDL. Abstract A-105. http://www.aacc.org/events/annualmtgdirectory/Documents/AACC-12-Abstracts-A77- A119.pdf [accessed 15.08.13].
47. Stein EA, Wasserman SM, Bridges I. Calculated LDL cholesterol by Friedewald substantially underestimates LDL-C below 70 mg/dL 81st congress of the European Atherosclerosis Society, Lyon, France; June 2-5, 2013. http://w3.kenes-group.com/apps/eas2013/abstracts/pdf/10.pdf [accessed 01.10.13].
48. J.J.P. Kastelein, W.A. van der Steeg, and I. Holme et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment Circulation 117 2008 3002 3009
49. Z. Zhao, Y. Tuakli-Wosornu, and T.A. Lagace et al. Molecular characterization of loss-of function mutations in PCSK9 and identification of a compound heterozygote Am J Hum Genet 79 2006 514 523
50. A.J. Hooper, A.D. Marais, and D.M. Tanyanyiwa et al. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population Atherosclerosis 193 2007 445 448
51. D.R. Jacobs, H. Blackburn, and M. Higgins et al. Report of the conference on low blood cholesterol: mortality associations Circulation 86 1992 1046 1060
52. J. Pekkanen, A. Nissinen, and E. Vartiainen et al. Changes in serum cholesterol level and mortality: a 30-year follow-up: the Finnish Cohorts of the Seven Countries Study Am J Epidemiol 139 1994 155 165
53. C. Iribarren, D.M. Reed, and R. Chen et al. Low cholesterol and mortality: which is the cause and which is the effect? Circulation 92 1995 2396 2403
54. Report from the Committee of Principal Investigators A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate Br Heart J 40 1978 1069 1118
55. M. Miettinen, O. Turpeinen, and M.J. Karvonen et al. Effect of cholesterol-lowering diet on mortality from coronary heart disease and other causes. A 12 year clinical trial in men and women Lancet 2 1972 835 838
56. S. Dayton, M.L. Pearce, and S. Hashimoto et al. A controlled clinical trial of a diet high in unsaturated fat in preventing complications of atherosclerosis Circulation 39/40 Suppl. II 1969 1 63
57. A.A. Alsheikh-Ali, P.V. Maddukuri, and H. Han et al. Effect of magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer J Am Coll Cardiol 50 2007 409 418
58. M.F. Muldoon, S.B. Manuck, and K.A. Matthews Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials BMJ 301 1990 309 314
59. H. Iso, D.R. Jacobs, and D. Wentworth et al. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the MRFIT N Engl J Med 320 1989 904 910
60. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators High-dose atorvastatin after stroke or transient ischemic attack N Engl J Med 355 2006 549 559
61. N. Sattar, D. Preiss, and H.M. Murray et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 2010 735 742
62. D. Preiss, S.R. Seshasai, and P. Welsh et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis JAMA 305 2011 2556 2564
63. FDA Drug Safety Communication: important safety label changes to cholesterol-lowering statin drugs. http://www.fda.gov/Drugs/DrugSafety/ ucm293101.htm [accessed 01.10.13].
64. B. Staels, and F. Kuipers Bile acid sequestrants and the treatment of type 2 diabetes mellitus Drugs 67 2007 1383 1392
65. M.S. Brown, and J.L. Goldstein A receptor-mediated pathway for cholesterol homeostasis Science 232 1986 34 47
66. N.J. Leeper, R. Ardehall, and E.M. deGoma et al. Statin use in patients with extremely low low-density lipoprotein levels is associated with improved survival Circulation 116 2007 613 618